• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

Archive

The ECG-GABA Research Award for Gerodontology worth five thousand Swiss francs was recently presented for the third time by the European College of Gerodontology ECG and GABA.

The new meridol® perio special toothbrush with its microfine bristle ends supports the healing process in the event of sensitive gingiva.

The North Rhine-Westphalia Design Centre has singled out the new elmex® interdental brush as a winner of its coveted “red dot award” in product design.

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration FDA has granted accelerated approval of Aptivus tipranavir capsules.

Boehringer Ingelheim announced today to publish with in the next weeks their clinical trials online.

New research data on pramipexole show 95 percent effectiveness and long-term relief from the symptoms of Restless Legs Syndrome

ASTRAZENECA S BREAST CANCER TREATMENT ARIMIDEX® GRANTED NEW INDICATION ENABLING WIDER ACCESS FOR POSTMENOPAUSAL WOMEN

Medical device company Astra Tech AB, a subsidiary of AstraZeneca PLC, is acquiring Cresco Ti Systems from its primary owners SEB Företagsinvest, Credit Suisse Innoventure Capital AG, and Banque Cantonale Vaudoise.

AstraZeneca announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 – now to be known by its trade name, ZACTIMATM.

AstraZeneca today announced an exclusive global licensing and research collaboration agreement with Avanir to discover, develop and commercialise Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.